# US 12,215,149 B2 · Anti-MS4A6A antibodies and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,215,149 B2
- Document ID: US12215149B2
- Status: Granted
- Kind: B2
- Application number: 17/722,624
- Filed: 2022-04-18
- Published: 2022-12-01
- Granted: 2025-02-04
- Earliest claimed: 2018-01-31
- Assignees: Alector LLC
- Applicants: Alector LLC
- Inventors: Philip Kong; Herve Rhinn; Tina Schwabe; Angie Yee; Arnon Rosenthal
- Web page: https://patentgrep.com/patent/US12215149B2

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 2039/505: {comprising antibodies}
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A6A polypeptide, e g., a mammalian MS4A6A or human MS4A6A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

## Claims

### Claim 1

An isolated antibody that binds to human MS4A6A, wherein the antibody comprises a heavy chain variable region and a light chain variable region, wherein:
(i) the heavy chain variable region comprises
an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 14;
an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 29;
an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 43; and
the light chain variable region comprises:
an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 57;
an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 73; and
an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 84;
or
(ii) the heavy chain variable region comprises:
an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 11;
an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 24;
an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39; and
the light chain variable region comprises:
an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 53;
an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 68; and
an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 84.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein the antibody comprises
an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 14;
an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 29;
an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 43;
an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 57;
an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 73; and
an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 84.

### Claim 3 (depends on 2)

The antibody of claim 2, wherein the heavy chain variable region and light chain variable region comprise the amino acid sequences of SEQ ID NOs: 104 and 121, respectively.

### Claim 4 (depends on 2)

The antibody of claim 2, wherein the antibody is a monoclonal antibody.

### Claim 5 (depends on 3)

The antibody of claim 3, wherein the antibody is of the IgG class, the IgM class, or the IgA class.

### Claim 6 (depends on 5)

The antibody of claim 5, wherein the antibody is of the IgG class and has an IgG1, IgG2, or IgG4 isotype.

### Claim 7 (depends on 3)

The antibody of claim 3, wherein the antibody is an antibody fragment.

### Claim 8 (depends on 7)

The antibody of claim 7, wherein the fragment is a Fab, Fab′, Fab′-SH, F(ab′)2, Fv or scFv fragment.

### Claim 9 (depends on 2)

The antibody of claim 2, wherein the antibody is a multispecific antibody comprising a first antigen binding region that binds to MS4A6A and a second antigen binding region that binds to a second target, wherein the second target is
a protein, lipid, polysaccharide, or glycolipid expressed on one or more tumor cells.

### Claim 10 (depends on 2)

A pharmaceutical composition comprising the antibody of claim 2 and a pharmaceutically acceptable carrier.

### Claim 11 (depends on 3)

A pharmaceutical composition comprising the antibody of claim 3 and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 1)

The antibody of claim 1, wherein the antibody comprises
an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 11;
an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 24;
an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 39;
an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 53;
an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 68; and
an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 84.

### Claim 13 (depends on 12)

The antibody of claim 12, wherein the heavy chain variable region and light chain variable region comprises the amino acid sequences of SEQ ID NOs: 98 and 116, respectively.

### Claim 14 (depends on 13)

The antibody of claim 13, wherein the antibody is of the IgG class, the IgM class, or the IgA class.

### Claim 15 (depends on 14)

The antibody of claim 14, wherein the antibody is of the IgG class and has an IgG1, IgG2, or IgG4 isotype.

### Claim 16 (depends on 13)

The antibody of claim 13, wherein the antibody is an antibody fragment.

### Claim 17 (depends on 16)

The antibody of claim 16, wherein the fragment is a Fab, Fab′, Fab′-SH, F (ab′) 2, Fv or scFv fragment.

### Claim 18 (depends on 12)

A pharmaceutical composition comprising the antibody of claim 12 and a pharmaceutically acceptable carrier.

### Claim 19 (depends on 14)

A pharmaceutical composition comprising the antibody of claim 14 and a pharmaceutically acceptable carrier.